EUCTR2004-004744-43-NO
Active, not recruiting
Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor/Idiopathic Rhinitis
ConditionsVasomotor/Idiopathic Rhinitis
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Vasomotor/Idiopathic Rhinitis
- Sponsor
- GlaxoSmithKline Research & Development Ltd
- Enrollment
- 347
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject will be eligible for inclusion only if all of following criteria apply:
- •1\. Informed consent
- •Subject has provided an appropriately signed and dated informed consent. An
- •appropriately signed and dated assent must be obtained from the parents or
- •guardian if the subject is a child under 18 years of age.
- •2\. Subject is treatable on an outpatient basis.
- •3\. Age \- \= 12 years at Visit 2
- •4\. Male or eligible female
- •To be eligible for entry, females of childbearing potential must commit
- •to consistent and correct use of an acceptable method of birth control, as defined
Exclusion Criteria
- •Subject will not be eligible for inclusion if any of following criteria apply:
- •1\. Significant concomitant medical conditions, defined as but not limited to:
- •a Historical/current evidence of clinically significant uncontrolled disease of
- •any body system. Significant is defined as any disease that, in the opinion of
- •investigator, would put safety of subject at risk through study
- •participation or which would confound the interpretation of study results if
- •disease/condition exacerbated during study.
- •b severe physical obstruction of the nose/nasal septal perforation that could
- •affect deposition of double blind intranasal study drug
- •c nasal/throat injury or surgery in last 3 mths
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Efficacy and Safety of REGN727/SAR236553 Versus Placebo in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled with Their Lipid-Modifying TherapyEUCTR2012-001222-95-NLRegeneron Pharmaceuticals Inc.250
Active, not recruiting
Phase 1
A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Glucose Transporter Type 1 deficiency syndromeMedDRA version: 17.1 Level: HLGT Classification code 10039911 Term: Seizures (incl subtypes) System Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2013-003771-35-GBltragenyx Pharmaceutical Inc36
Active, not recruiting
Phase 1
Safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (liver disease) from nonalcoholic steatohepatitis (NASH).Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)MedDRA version: 20.0Level: HLTClassification code 10019669Term: Hepatic fibrosis and cirrhosisSystem Organ Class: 100000004871MedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 100000004871Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2019-003932-22-DEBristol-Myers Squibb International Corporation270
Active, not recruiting
Not Applicable
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR)Perennial Allergic Rhinitis (PAR) in adults and children of 12 years and older.MedDRA version: 9.1Level: LLTClassification code 10034382Term: Perennial allergic rhinitisEUCTR2007-006562-15-EEGlaxoSmithKline Research & Development Ltd288
Active, not recruiting
Phase 1
Baricitinib in Patients with COVID-19 InfectioCOVID-19 infectionMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-001517-21-DEEli Lilly and Company1,400